Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas

• DOI: 10.1016/j.jaccao.2023.11.007
• Publication Date: 2024-01-16T18:59:14Z
• Authors: Amin H. Nassar; Edward El-Am; Ryan Denu; Sarah Abou Alaiwi; Talal El Zarif; Walid Macaron; Noha Abdel-Wahab; Aakash Desai; Caleb Smith; Kaushal Parikh; Muhannad Abbasi; Elias Bou Farhat; James M. Williams; Jeremy D. Collins; Ahmad Al-Hader; Rana R. McKay; Carmel Malvar; Mohamad Sabra; Caiwei Zhong; Raquelle El Alam; Omar Chehab; Joao Lima; Minh Phan; Hanna Ferreira Da...; Alexandra Trevino; Tomas G. Neilan; Jennifer M. Kwan; Vinod Ravi; Hari Deshpande; George Demetri; Toni K. Choueiri; Abdul Rafeh Naqash

Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes. The aim of this study was to investigate the clinical outcomes patients CSTS receiving immune checkpoint inhibitors (ICIs). A retrospective, multi-institutional cohort conducted among between 2015 and 2022. were treated ICI-based regimens. Kaplan-Meier method used estimate overall survival (OS) progression-free (PFS). Objective response rates determined according Response Evaluation Criteria in Solid Tumors version 1.1. Treatment-related adverse events graded per Common Terminology for Adverse Events 5.0. Among 24 CSTS, 17 (70.8%) White, 13 (54.2%) male. Eight (33.3%) had angiosarcoma. At time ICI treatment, 18 (75.0%) metastatic 4 (16.7%) locally advanced disease. ICIs administered as first-line therapy 6 (25.0%) second-line or beyond (75.0%). For available data, objective rate 11.1% (n = 2 18). median PFS OS 22) 5.7 months (95% CI: 2.8-13.3 months) 14.9 5.7-23.7 months), respectively. significantly shorter angiosarcomas than those nonangiosarcoma CSTS: 1.7 vs 11 months, respectively (P < 0.0001), 3.0 24.0 0.008). Any grade treatment-related occurred exclusively 15 7 [46.7%]), which (40.0%) ≥3. Although demonstrate modest activity durable benefit observed a subset nonangiosarcoma, albeit higher toxicity.